Disruption of chromatin organisation causes MEF2C gene overexpression in intellectual disability: a case report.


Journal

BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628

Informations de publication

Date de publication:
02 08 2019
Historique:
received: 23 01 2019
accepted: 15 07 2019
entrez: 4 8 2019
pubmed: 4 8 2019
medline: 31 1 2020
Statut: epublish

Résumé

Balanced structural variants are mostly described in disease with gene disruption or subtle rearrangement at breakpoints. Here we report a patient with mild intellectual deficiency who carries a de novo balanced translocation t(3;5). Breakpoints were fully explored by microarray, Array Painting and Sanger sequencing. No gene disruption was found but the chromosome 5 breakpoint was localized 228-kb upstream of the MEF2C gene. The predicted Topologically Associated Domains analysis shows that it contains only the MEF2C gene and a long non-coding RNA LINC01226. RNA studies looking for MEF2C gene expression revealed an overexpression of MEF2C in the lymphoblastoid cell line of the patient. Pathogenicity of MEF2C overexpression is still unclear as only four patients with mild intellectual deficiency carrying 5q14.3 microduplications containing MEF2C are described in the literature. The microduplications in these individuals also contain other genes expressed in the brain. The patient presented the same phenotype as 5q14.3 microduplication patients. We report the first case of a balanced translocation leading to an overexpression of MEF2C similar to a functional duplication.

Sections du résumé

BACKGROUND
Balanced structural variants are mostly described in disease with gene disruption or subtle rearrangement at breakpoints.
CASE PRESENTATION
Here we report a patient with mild intellectual deficiency who carries a de novo balanced translocation t(3;5). Breakpoints were fully explored by microarray, Array Painting and Sanger sequencing. No gene disruption was found but the chromosome 5 breakpoint was localized 228-kb upstream of the MEF2C gene. The predicted Topologically Associated Domains analysis shows that it contains only the MEF2C gene and a long non-coding RNA LINC01226. RNA studies looking for MEF2C gene expression revealed an overexpression of MEF2C in the lymphoblastoid cell line of the patient.
CONCLUSIONS
Pathogenicity of MEF2C overexpression is still unclear as only four patients with mild intellectual deficiency carrying 5q14.3 microduplications containing MEF2C are described in the literature. The microduplications in these individuals also contain other genes expressed in the brain. The patient presented the same phenotype as 5q14.3 microduplication patients. We report the first case of a balanced translocation leading to an overexpression of MEF2C similar to a functional duplication.

Identifiants

pubmed: 31375103
doi: 10.1186/s12920-019-0558-8
pii: 10.1186/s12920-019-0558-8
pmc: PMC6679470
doi:

Substances chimiques

Chromatin 0
MEF2 Transcription Factors 0
MEF2C protein, human 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

116

Références

J Pediatr Genet. 2017 Sep;6(3):129-141
pubmed: 28794905
Am J Med Genet A. 2006 Oct 1;140(19):2063-74
pubmed: 16917849
Nat Genet. 2017 Jan;49(1):36-45
pubmed: 27841880
Nature. 2016 Oct 13;538(7624):265-269
pubmed: 27706140
Hum Genet. 1998 Aug;103(2):173-8
pubmed: 9760201
Cell. 2015 May 21;161(5):1012-1025
pubmed: 25959774
Am J Hum Genet. 2006 Aug;79(2):370-7
pubmed: 16826528
Nucleic Acids Res. 2018 Jan 4;46(D1):D794-D801
pubmed: 29126249
Eur J Hum Genet. 2015 Jul;23(7):915-21
pubmed: 25315662
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Trends Genet. 2016 Apr;32(4):225-237
pubmed: 26862051
J Neurodev Disord. 2015;7(1):26
pubmed: 26257835
Ann Neurol. 2009 Dec;66(6):771-82
pubmed: 20035514
Cell Rep. 2017 Feb 28;18(9):2280-2288
pubmed: 28249171
Hum Mol Genet. 1998;7(10):1611-8
pubmed: 9735382
Database (Oxford). 2017 Jan 1;2017:
pubmed: 28605766
Eur J Med Genet. 2009 Sep-Oct;52(5):291-6
pubmed: 19505601
J Med Genet. 2010 Jan;47(1):22-9
pubmed: 19592390
Nat Rev Genet. 2016 Jan;17(1):9-18
pubmed: 26503795
Genome Biol. 2018 Oct 4;19(1):151
pubmed: 30286773
Am J Med Genet A. 2016 May;170A(5):1352-7
pubmed: 26864752
Nat Rev Genet. 2018 Jul;19(7):453-467
pubmed: 29692413
Am J Med Genet. 2002 Sep 1;111(4):405-8
pubmed: 12210300
Hum Mutat. 2010 Jun;31(6):722-33
pubmed: 20513142
J Med Genet. 2013 Aug;50(8):543-51
pubmed: 23749989
Eur J Med Genet. 2013 May;56(5):260-5
pubmed: 23402836

Auteurs

Kevin Yauy (K)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Anouck Schneider (A)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Bee Ling Ng (BL)

Cytometry Core Facility, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.

Jean-Baptiste Gaillard (JB)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Satish Sati (S)

Chromatin and Cell Biology Group, CNRS-Institute of Human Genetics, Montpellier, France.

Christine Coubes (C)

Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Constance Wells (C)

Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Magali Tournaire (M)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Thomas Guignard (T)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Pauline Bouret (P)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

David Geneviève (D)

Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Jacques Puechberty (J)

Service de Génétique Clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Franck Pellestor (F)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.

Vincent Gatinois (V)

Unité de Génétique Chromosomique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France. vincent.gatinois@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH